Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Neoplasm Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00151073
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer
Interventions
Zoledronic acid, Estramustine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NCT04009083
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 29, 2026, 10:22 AM EDT
Withdrawn Phase 1 Interventional

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

NCT02182622
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Prednisone, LDE225
Drug
Lead sponsor
Martin Gutierrez
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 29, 2026, 10:22 AM EDT
Active, not recruiting Phase 1 Interventional

TH1902 in Patients With Advanced Solid Tumors

NCT04706962
View directory record Official record
Conditions
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Interventions
TH1902
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 29, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

NCT05926102
View directory record Official record
Conditions
Prostate Cancer
Interventions
Precision screening intervention, Usual care
Genetic · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 69 Years · Male only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DM002 in Patients With Advanced Solid Tumors

NCT06751329
View directory record Official record
Conditions
Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms, Solid Carcinoma, Pancreatic Cancer
Interventions
DM002
Drug
Lead sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • Huntersville, North Carolina • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

NCT04189770
View directory record Official record
Conditions
Cancer Survivor, Partner, Spouse, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Accelerometer, Ecological Momentary Assessment, Questionnaire Administration, Survey Administration
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Not yet recruiting Not applicable Interventional

RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer)

NCT07440641
View directory record Official record
Conditions
Prostate Cancer
Interventions
Remote Supervised Exercise Program
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
55 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

NCT00036556
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
94
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2007 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551
View directory record Official record
Conditions
Prostate Cancer
Interventions
Peptide Vaccine, Poly IC-LC
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 29, 2026, 10:22 AM EDT
Active, not recruiting No phase listed Observational

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

NCT05424783
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 76 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

NCT00085566
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 29, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

NCT07231627
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bi-parametric MRI-based cascaded deep-learning AI algorithm
Device
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

NCT00140478
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of Prostate
Interventions
Mifepristone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 29, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

NCT00588185
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Withdrawn No phase listed Observational

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

NCT06804785
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Enzalutamide, Erdafitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
PLX2853 20 mg, Olaparib, Abiraterone acetate, Prednisone, PLX2853 40 mg, PLX2853 80 mg
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Chicago, Illinois • Detroit, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 29, 2026, 10:22 AM EDT
Not yet recruiting Not applicable Interventional

ExosomeDx in MRI-negative Men With High PSA

NCT06966089
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
Device · Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 29, 2026, 10:22 AM EDT
Completed No phase listed Observational

Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols

NCT00026689
View directory record Official record
Conditions
Prostate, Brain, Breast, Lung, Endometrial
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 90 Years
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 29, 2026, 10:22 AM EDT
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 29, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Perioperative Post-Prostatectomy Incontinence Home Telehealth Program

NCT01960998
View directory record Official record
Conditions
Urinary Incontinence, Prostate Cancer
Interventions
Pelvic Floor Muscle Training, Perioperative Care and Wetness Management
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Male only
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Decatur, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 29, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

NCT01335204
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Cabazitaxel plus bavituximab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 29, 2026, 10:22 AM EDT